open access

Vol 5, No 1 (2009)
Guidelines / Expert consensus
Published online: 2009-02-02
Get Citation

Proposal of defining colorectal cancer subpopulation potentially recommended to bevacizumab treatment. Statement of clinical oncology Advisory Board at Roche Polska Sp. z o.o.

Krzysztof Krzemieniecki, Andrzej Deptała, Kazimierz Drosik, Maria Litwiniuk, Wojciech Rogowski
Onkol. Prak. Klin 2009;5(1):16-19.

open access

Vol 5, No 1 (2009)
EXPERTS' OPINION
Published online: 2009-02-02

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Proposal of defining colorectal cancer subpopulation potentially recommended to bevacizumab treatment. Statement of clinical oncology Advisory Board at Roche Polska Sp. z o.o.

Journal

Oncology in Clinical Practice

Issue

Vol 5, No 1 (2009)

Article type

Guidelines / Expert consensus

Pages

16-19

Published online

2009-02-02

Bibliographic record

Onkol. Prak. Klin 2009;5(1):16-19.

Authors

Krzysztof Krzemieniecki
Andrzej Deptała
Kazimierz Drosik
Maria Litwiniuk
Wojciech Rogowski

References (2)
  1. Khrizman P, Niland JC, ter Veer A, et al. National Comprehensive Cancer Network. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. Pharmacotherapy. 2008; 28(11 Pt 2): 18S–22S.
  2. Chase JL. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy. 2008; 28(11 Pt 2): 23S–30S.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl